Abbisko Cayman Limited (HK:2256) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbisko Cayman Limited has announced the initiation of a Phase II clinical trial for its oral drugs ABSK061 and ABSK043, aimed at treating metastatic or unresectable solid tumors with FGFR2/3 alterations. These drugs have shown promising anti-tumor activity and a favorable safety profile in previous studies, making this trial a significant development for potential cancer treatments. Investors are advised to be cautious as the drugs are still under clinical evaluation.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.